Mark B. Faries

Jul 6, 2023 | fal.cn | Xiaoran Zhang |Laura J. Ferris |Mark B. Faries |Jason Luke

The Case for Continuous Use of SLNBThe value of pathologically staged regional lymph nodes should not be underestimated. The MSS of stage IIB/C patients who might consider the newly approved adjuvant regimens should not be compared with that of stage IIIA patients as a SLN metastasis would upstage them to either stage IIIC or IIID.